Innate Pursues Anti-Leukemic In EU
Lumoxiti Potentially Transformative For French Firm
Executive Summary
Innate Pharma pursues refractory hairy cell leukemia opportunity with first-in-class CD22-directed immunotoxin, moxetumomab pasudotox-tdfk.
You may also be interested in...
AstraZeneca Pulls Plug On Lumoxiti Due To Low Uptake
Signs of trouble were already emerging in 2020 when Innate backed out of a co-commercialization pact. AstraZeneca plans to discontinue the hairy cell leukemia ADC in July.
AstraZeneca And Galapagos Shine At The 15th Annual Scrip Awards
The pharma, biotech and allied industries came together in London on 4 December to celebrate another year of achievement at the 15th Annual Scrip Awards, hosted by the broadcaster Fiona Bruce.
Ten Strategies For Success In Antibody-Drug Conjugate Development
The future looks rosy after a slow start for antibody-drug conjugates. But what are the best tactics to capture a slice of the growing opportunity?